Skip to content
Search

Latest Stories

Fintech firms can help prevent digital frauds, says RBI deputy governor

Fintech firms can help prevent digital frauds, says RBI deputy governor

DIGITAL frauds have surged during the Covid-19 pandemic and fintech firms can play a significant role in preventing this, Reserve Bank of India (RBI) deputy governor said Tuesday (28).

T Rabi Sankar said that digital penetration is largely limited to urban and metro areas and needed to be expanded to the entire country.


"We need technological solutions to increase penetration to the vast sections of the population, which is unbanked and lacks a smartphone," Sankar said.

According to him, the pace of digital penetration has outstripped awareness.

He said: "We need to concentrate and focus all our attention on minimising digital fraud... We need to up our guard against digital frauds and cybercrime. Both regulators and other stakeholders have to play their respective roles effectively to ensure that innovation in the fintech space continues to support India's economic growth.

"We are in the best of times, with the promise of technological innovation in finance and hope of substantial efficiency gains, better customer experience and greater social welfare, but we also need to deal with the threats of online frauds, compromise of customer credentials, data privacy, and safety."

The RBI official also pointed out that fintech can play an important role in real-time cross-border payments, which have stagnated for decades.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less